Meet Sprout


We’re committed to breakthrough firsts in women’s sexual health.

Sit At Our Glass Table

Novel ideas fuel our entrepreneurial passion. Sit with us at our glass table, where we have lunch together daily, to get a taste of our culture. At Sprout, we celebrate ownership, boldness, quirkiness, learning, family and appreciation. They are central to what we stand for and what we’re trying to collectively accomplish.

We’re On A Mission


Singular in our focus, our leadership team sold off a successful business in male sexual health to take on the pursuit of this much needed scientific and societal breakthrough for women. Led by a woman dedicated to this first for women, our CEO, Cindy Whitehead, and the work of the committed Sprout team has been featured on news outlets including ABC 20/20, Yahoo! News with Katie Couric, Good Morning America, Nightline, Huffington Post, and CBS This Morning.

We'd Love to Hear From You

Share your story (thank you to all the women and couples who already have!), your interest in joining us or your inquiries. We’d love to hear from you!

To Join Us, click here.

Learn Our Latest


Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

Enters Sexual Health Market with FDA-Approved Addyi™ (flibanserin 100mg) ADDYI Expected to Launch in U.S. in the Fourth Quarter of 2015 Laval, Quebec and Raleigh, NC — August 20, 2015 — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones. On Tuesday, August 18, 2015, Sprout received approval from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for flibanserin, which will be marketed as Addyi in the U.S. Addyi has demonstrated improvements in desire for sex, reducing distress from the loss of sexual desire and increasing the number of satisfying sexual events. Sprout also has global rights for flibanserin. Valeant will leverage its global scale to register flibanserin internationally. Sprout is passionate about women’s sexual health and has focused solely on the delivery of a treatment option for the unmet need of premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. Addyi is not indicated for use in postmenopausal women or men or to enhance sexual function. Addyi was approved with a Boxed Warning. Use of Addyi with alcohol increases the risk of severe hypotension and syncope; therefore, alcohol...

Sprout Pharmaceuticals Receives FDA Approval of ADDYI™ (Flibanserin 100 MG)

First-ever FDA-approved treatment for women’s most common form of sexual dysfunction Raleigh, N.C. – August 18, 2015 – Sprout Pharmaceuticals, Inc. (Sprout) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of Addyi™ (flibanserin 100 mg) (pronounced add-ee), a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Addyi is the first and only FDA-approved treatment for this condition, the most common form of female sexual dysfunction, affecting up to 1 in 10 women in the United States.1 “It has been a remarkable journey to get to this breakthrough moment. Today we celebrate what this approval means for all women who have long awaited a medical treatment option for this life impacting condition,” said Cindy Whitehead, chief executive officer of Sprout. “We applaud the FDA for putting the patient voice at the center of the conversation and for focusing on scientific evidence.” HSDD is defined as a persistent absence of sexual thoughts, fantasies, responsiveness and willingness to engage in sexual activity that causes personal or relationship distress and cannot be accounted for by another medical condition or substance.2 Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.3 Flibanserin has been studied in more than 11,000 women.4 The FDA approval of Addyi is largely based on three North American, Phase 3, 24-week, randomized double blind, placebo-controlled, studies of premenopausal women with HSDD. For premenopausal women with HSDD, Addyi has demonstrated improvements in desire...